Research on ER-positive breast cancer (cell line MCF-7 xenografts) demonstrated that tamoxifen, a selective ER modulator, effectively inhibits classical ER-dependent transcription, including the transcription of IGF1R gene product [92]. Here, ESR1 is linked to breast carcinoma.